Clinical Trials
Last Updated: 4/4/2013
Leukemia Clinical Trials are Grouped by Disease Type:
- Phase I Agents
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Myeloproliferative Diseases
Phase I Agents
- L-Grb2 Antisense Oligonucleotide (ALL, AML, MDS, CML) (2003-0578)
- A-dmDT390-bisFv (UCHT1) Fusion Protein (ALL, CLL) (2008-0077)
- G-CSF & Plerixafor + Sorafenib (AML) (2008-0501)
- Hyper-CVAD + RAD001 (everolimus) (ALL) (2009-0100)
- Vidaza + Revlimid (AML, MDS) (2009-0467)
- Plerixafor + Clofarabine (AML) (2009-0536)
- Randomized Aza +/- LBH (AML, MDS) (2009-0619)
- Nelarabine (2009-0717)
- ABT-348 (AML, ALL, CLL, CML, MDS) (2009-0788)
- LY2784544 (MDP) (2010-0167)
- TH-302 (ALL, AML, MDS, CLL, CML, MPD) (2010-0268)
- PCK412 and AZA (AML, MDS) (2010-0374)
- KB004 (ALL, AML, MDS, CLL, CML, MPD) (2010-0509)
- Sorafenib + 5 Aza (AML, MDS) (2010-0511)
- SGI-110 (AML, MDS) (2010-0615)
- CIA vs FLAI (2010-0788)
- BKM120 (ALL, AML) (2010-0874)
- INC424 (MPD) (2010-0964)
- PM01183 (AML, ALL, MDS, CML) (2010-0965)
- Plerixafor + G-CSF (AML) (2011-0036)
- AC220 (ASP2689) (AML, CML) (2011-0041)
- Ara-C + Tosedostat (AML, MDS) (2011-0188)
- CWP232291 (AML) (2011-0253)
- Dasatinib + DAC (2011-0333)
- AMG 900 (AML, ALL, MDS, CML) (2011-0369)
- BMS-906024 -Notch inhibitor (ALL) (2011-0382)
- PRI-724 (AML, CML, MDS, MPD) (2011-0527)
- MK-8242 (AML) (2011-0547)
- AZD1208 (AML, MDS, MPN, CML) (2011-0816)
- ARRY-614 (MDS) (2011-0827)
- Rituximab (ALL) (2011-0844)
- DAC + Clofarabine + IDA + Ara-C (2012-1064)
- DFP-10917 (ALL, AML) (2012-0262)
- TRU-016 + Rituximab (2012-0626)
- IPI-145 (2012-1040)
Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed or Previously Treated
- Augmented Berlin-Frankfurt-Munster (2006-0375)
- Hyper-CVAD + Ofatumumab (2010-0708)
- Marqibo (2011-1071)
- Hyper-CVAD + Inotuzumab Ozogamycin (CMC-544) (2010-0991)
- Hyper-CVAD + Nelarabine (2006-0328)
- Hyper-CVAD + Ponatinib +/- Rituximab (2011-0030)
- Hyper-CVAD + Dasatinib (SWOG0805)
Salvage Programs
- Inotuzumab Ozogamicin (2012-0151)
- Blinatumomab (BiTE) (2011-0784)
- SAR 3419 (2011-0287)
- BKM120 (2010-0874)
- Rituximab (ALL) (2011-0844)
- Hyper-CVAD + Dasatinib (2006-0478)
- BKM120 (2010-0874)
- Nelarabine (2009-0717)
- PF-03084014 (2010-0317)
- BMS-906024 - Notch inhibitor (2011-0382)
- A-dmDT390-bisFv (UCHT1) Fusion Protein (ALL, CLL) (2008-0077)
- BKM120 (2010-0874)
- Hyper-CVAD + RAD001 (everolimus) (2009-0100)
- MOAD (2008-0267)
- Hyper-CVAD + Inotuzumab Ozogamycin (CMC-544) (2010-0991)
- Rituximab (ALL) (2011-0844)
Acute Myelogenous Leukemia (AML)
Newly Diagnosed
- Fludarabine, Ara-C, G-CSF and Gemtuzumab Ozogamicin (2007-0147)
- ATRA and arsenic +/- Gemtuzumab Ozogamicin (2010-0981)
- AC220 (ASP2689) (2011-0041)
- CIA vs FLAI (2010-0788)
- PF-04449913 (2012-0062)
- LD Ara-C + Lintuzumab-Ac225 (2012-0434)
- Omacetazine + LD Ara-C (2010-0736)
- DAC (2012-1017)
- Plerixafor + Clofarabine (2009-0536)
- Cladribine + LD Ara-C alternating DAC (2011-0987)
- Sorafenib + 5 Azacitidine (2010-0511)
- Vidaza + Revlimid (2009-0467)
- PF-04449913 (2012-0062)
- SGI-110 (AML, MDS) (2010-0615)
- Sapacitabine alternating DAC (2010-0727)
Newly Diagnosed FLT3 Mutated
Unfit for induction chemotherapy
- Vorinostat + Aza (2007-0685)
Frontline AML Post-Hypomethylating Therapy for MDS
- PF-04449913 (2012-0062)
- LD Ara-C + Lintuzumab-Ac225 (2012-0434)
- Ara-C + Tosedostat (AML, MDS) (2011-0188)
Salvage
- Oral Tamibarotene (APL) (2007-0512)
- G-CSF & Plerixafor + Sorafenib (2008-0501)
- Crenolanib (2012-0569)
- PCK412 and AZA (2010-0374)
- Vosaroxin + Ara-C vs Placebo + Ara-C (2010-0692)
- Plerixafor + G-CSF (AML) (2011-0036)
- DAC + Clofarabine + IDA + Ara-C (2012-1064)
- CIA vs FLAI (2010-0788)
- Ondansetron vs Ondansetron + aprepitant (2008-0615)
Secondary Leukemia
- CPX-351 vs Ara-C + Daunorubicin (2012-0980)
Maintenance (Patients in CR)
- Oral AZA + BSC vs BSC as maintenance in AML in CR (2012-0866)
Myelodysplastic Syndrome (MDS) (Includes CMML)
- Vorinostat + Aza (2007-0685)
- Hypoplastic MDS - Alemtuzumab (2010-0187)
- Hypoplastic MDS and aplastic anemia - Horse ATG (2012-0334)
- MDS/MPN - Ruxolitinib + AZA (2012-0737)
Post Hypomethylating Agents:
- ARRY-614 (MDS) (2011-0827)
- ON 01910 vs Ara-C (2010-0209)
- Clofarabine + LD Ara-C (2011-0660)
- IPI-145 (2012-1040)
Specific
- Oral AZA + BSC vs Placebo + BSC (2012-0733)
- DAC VS AZA (2012-0507)
- ARRY-614 (MDS) (2011-0827)
- Lenalidomide VS Placebo (2009-0737)
- PCK412 and AZA (2010-0374)
- Deferasirox (2010-0041)
- SGI-110 (AML, MDS) (2010-0615)
IPSS int-2 or high
- Vidaza + Revlimid (2009-0467)
- Randomized Azam +/- LBH (2009-0619)
- Randomized DAC alternating Clo vs DAC (2008-0092)
- SGI-110 (AML, MDS) (2010-0615)
- Sapacitabine alternating DAC (2010-0727)
- Cladaribine + LD Ara-C alt. DAC (2011-0987)
- Omacetazine + LD Ara-C (2010-0736)
- PF-04449913 (2012-0062)
- Plerixafor + Clofarabine (2009-0536)
- CIA vs FLAI (2010-0788)
- E7070 + Ida + Ara-C (2009-0570)
- CPX-351 vs Ara-C + Daunorubicin (2012-0980)
Chronic Lymphocytic Leukemia (CLL)
CLL Immunotherapy
Untreated - early stage
- Ofatumumab (2010-0241)
Untreated - all stages
- FCR (2008-0431)
- TRU-016 + Rituximab (2012-0626)
- PCI-32765 + Heavy Water (2012-0086)
- Lenalidomide + Rituximab (2011-0509)
- Ofatumumab (2011-0520)
Mimimal Residual Disease
- Revlimid (2007-0213)
Prior Therapy
- 8-Chloro-Adenosine (2004-0144)
- Ibrutinib vs Ofatumumab (2012-0707)
- Lenalidomide + Rituximab (2011-0509)
- ABT-199 (2011-0164)
- Fludarabine + bendamustine + rituximab (2009-0546)
- Sapacitabine + Cyclophosphamide + Rituximab (2010-0516)
- AVL-292 (2011-0513)
- GS-1101 (CAL-101) (2012-0411)
- PCI - 32765 (Extension Study) (2011-0142LEUKEMIA)
- GS-1101 (CAL-101) (2012-0171)
Previously Treated with 17p Deletion
- PCI-32765 (Ibrutinib) (2012-1125)
Supportive Care
- Eltrombopag (2010-0123)
Other Studies
- 2CDA + Rituximab (2004-0223)
Chronic Myelogenous Leukemia (CML)
Chronic phase
- Ponatinib (2012-0074)
- BMS-354825 (2005-0422)
- Dasatinib (2005-0422)
- Oral AMN107 (2005-0048)
- Ponatinib (2012-0669)
Accelerated Phase
- Dasatinib + DAC (2011-0333)
Blastic Phase
Minimal Residual Disease
Supportive Care
- Eltrombopag (2011-0319)
Other Studies
- Tryptophan Metabolism/Chronic Fatigue (2011-0559)
Myeloproliferative Diseases
- Ruxolitinib + AZA (2012-0737)
- Sotatercept (ACE-011) (2012-0534)
- Ruxolitinib + Revlimid (2011-0269)
- INCB039110 (2012-0035)
- SAR302503 (CMIF) (2011-0857)
- AB0024 (CIMF) (2011-0016)
- ruxolitinib (CIMF) (2011-0359)
- INC424 (CIMF) (2010-0964)
- IPI-145 (2012-1040)
- NS-018 (CIMF) (2011-0090)
- TH-302 (ALL, AML, MDS, CLL, CML, MPD) (2010-0268)
- BMS-911543 (CIMF) (2010-0782)
- PRI-724 (CIMF) (2011-0527)
- Ruxolitinib vs hydroxyurea (2012-0492)
- Masitinib vs Placebo (SM) (2008-0275)
- KB004 (2010-0509)
Previously Exposed to Ruxolitinib
- SAR302503 (2012-0065)
Supportive Care
Related Departments & Programs
Related Diseases
Leukemia Insights
Leukemia Insights is a quarterly newsletter for physicians and other health professionals. Insights has the latest leukemia news, research and results from ongoing clinical trials, and available leukemia programs at MD Anderson.

